ESMO News

Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC

1 day ago

Findings from the ASCENT-04/KEYNOTE-D19 study

FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer

2 days ago

ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer (EOC)

3 days ago

This Express Update has been issued following the approval of rucaparib as...

FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma

3 days ago

Evidence for efficacy is based on the results from the TRANSCEND FL-MZL...

ESMO Clinical Practice Guideline Express Update on the adoption of physical exercise in patients with localised colon cancer

4 days ago

Based on the phase III randomised controlled CHALLENGE trial, patients with resected...

Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing

4 days ago

Findings from the study on estimates of cancer mortality in 2026

Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas Harbouring NF2 or CDK Pathway Alterations

5 days ago

Findings from the Alliance A071401 study

N-of-1 Tailored Combination Therapy Matched to the Molecular Alterations, Facilitated by Personalised Dosing, Is Associated with Safety and Activity

8 days ago

Findings from the I-PREDICT study

European Parliament Adopts Its Position on the Critical Medicines Act, Strengthening Security of Cancer Care in Europe

9 days ago

The adopted text reinforces clinically grounded procurement, governance and solidarity mechanisms to...

FDA Grants Traditional Approval to Tarlatamab-dlle for Extensive Stage Small Cell Lung Cancer

9 days ago

Evidence for efficacy is based on the results from the DeLLphi-304 study

ESMO Raises Key Issues on Cancer Prevention and Care at the WHO Executive Board Meeting

10 days ago

ESMO regularly contributes to global health forums at the highest political level...

FDA Approves fam-Trastuzumab Deruxtecan-nxki with Pertuzumab for Unresectable or Metastatic HER2-positive Breast Cancer

10 days ago

Evidence for efficacy is based on the results from the DESTINY-Breast09 study